ProShares Ultra NASDAQ Biotechnology
BIB
20 hedge funds and large institutions have $5.9M invested in ProShares Ultra NASDAQ Biotechnology in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.
1.48% less ownership
Funds ownership: 8.72% → 7.24% (-1.5%)
20% less funds holding
Funds holding: 25 → 20 (-5)
28% less capital invested
Capital invested by funds: $8.16M → $5.9M (-$2.26M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
44% less call options, than puts
Call options by funds: $849K | Put options by funds: $1.52M
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$279K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$197K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$71.1K |
| 4 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$10.2K |
| 5 |
Morgan Stanley
New York
|
+$2.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
-$741K |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
-$392K |
| 3 |
Jane Street
New York
|
-$325K |
| 4 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$213K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$212K |
BIB Hedge Fund Activity: Q3 2023 in Review
20 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2023, worth a combined $5.9M — down 28% from $8.16M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIB and 2 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $279K. The largest seller was IMC Chicago, exiting entirely with an estimated $741K sold.
- 20 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2023, down from 25 in Q2 2023.
- Funds reported $5.9M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2023, down 28% quarter-over-quarter.
- 2 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2023 and 7 closed out, a net change of -5 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2023 was Tower Research Capital (TRC), an estimated $279K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2023 was IMC Chicago, an estimated $741K sold.
Based on aggregated 13F filings for Q3 2023.